News | January 18, 2009

First Patient Enrolled in EMBOLDEN Clinical Study for Efficacy of Gore Embolic Protection Device

January 19, 2009 - W.L. Gore and Associates today said Peter A. Soukas, M.D., an interventional cardiologist from Caritas St. Elizabeth’s Medical Center in Boston, MA, enrolled the first patient in the Gore EMBOLDEN Clinical Study Jan. 6.

The first patient was recently symptomatic and greater than 90 years old. The greater than 95 percent stenosis in the internal carotid artery was successfully stented under protection by the Gore Embolic Filter. The patient was discharged from the hospital and is doing well.

“In spite of the near total occlusion, the Gore Embolic Filter crossed easily and provided a stable platform for the remainder of the procedure,” Dr. Soukas said. “Moreover, the filter captured an impressive amount of embolic debris. One particularly large particle of plaque that was retrieved by the device would likely have put the patient at risk for a symptomatic event.”

“We are pleased to get this important study underway,” commented William A. Gray, M.D., Columbia University Medical Center, national principal investigator for the Gore EMBOLDEN Clinical Study. “Key device attributes, including low crossing profile, smooth tip transitions and reliable vessel wall apposition, were in evidence and proved beneficial in this challenging case.”

The Gore EMBOLDEN Clinical Study is a prospective, multi-center, nonrandomized, where the Gore Embolic Filter is used for neuroprotection during carotid artery stenting (CAS) in patients at high risk for carotid endarterectomy. The GORE Embolic Filter incorporates a unique diamond frame. The diamond frame is designed to optimize vessel wall apposition and filter efficiency, even in tortuous vessels with small landing zones and tight curves.

For more

Related Content

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices| October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices| October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices| June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Overlay Init